Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target.
Last updated: 2026-02-23 19:37:27 ET
Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target.
A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in later stages of the disease.
Abigail Shry was due to begin serving a 27-month federal prison sentence this week for threatening a federal judge, but she failed to appear.
The Technology is Impressive, But it’s Not Infallible Waymo’s autonomous vehicles are, by most technical measures, a remarkable achievement. Each ...